Moderna ( MRNA) Q4 & FY25 Outlook: - Q4 Results: - EPS: -2.91 (Missed Est. -2.68) - Revenue: 966M (Beat Est. 942.8M, -66% y/y) - COVID-19 Vaccine Revenue: 923M (In Line) - Net Product Sales: 938M - Operating Loss: -1.25B (Est. -1.13B, vs. 6M profit y/y) - Operating Expenses: 2.21B (-21% y/y, Est. 2.18B) - R&D Expenses: 1.12B (Est. 1.16B) - SG&A Expenses: 351M (-25% y/y, Est. 345.7M) - COGS: 739M (-20% y/y, Est. 580.5M) - Cash & Equivalents:** 1.93B (Est. 2.12B) - FY25 Guidance: - Revenue: 1.5B-2.5B (Est. 2.43B) - CapEx: ~400M (Est. 468.9M) - Cost Cuts: 1B by 2025-end - Cash & Investments (Dec 31):** 9.5B Q4 loss includes 200M in non-cash charges for manufacturing resizing.